2021
Wound formation, wound size, and progression of wound healing after intratumoral treatment of mast cell tumors in dogs with tigilanol tiglate
Reddell P, De Ridder TR, Morton JM, Jones PD, Campbell JE, Brown G, Johannes CM, Schmidt PF, Gordon V. Wound formation, wound size, and progression of wound healing after intratumoral treatment of mast cell tumors in dogs with tigilanol tiglate. Journal Of Veterinary Internal Medicine 2021, 35: 430-441. PMID: 33438258, PMCID: PMC7848365, DOI: 10.1111/jvim.16009.Peer-Reviewed Original ResearchConceptsMast cell tumorsPretreatment tumor volumeIntratumoral treatmentCell tumorsTigilanol tiglateTumor volumeWound areaWound management interventionsComplete tumor resolutionWound healingConsistent clinical patternTT treatmentTumor resolutionClinical patternClinical recordsSecondary intentionComplete resolutionClinical studiesMost dogsNecrotic tumorNovel small moleculesGranulation tissueWound sizeMost woundsTumors
2020
Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC‐46)
De Ridder TR, Campbell JE, Burke‐Schwarz C, Clegg D, Elliot EL, Geller S, Kozak W, Pittenger ST, Pruitt JB, Riehl J, White J, Wiest ML, Johannes CM, Morton J, Jones PD, Schmidt PF, Gordon V, Reddell P. Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC‐46). Journal Of Veterinary Internal Medicine 2020, 35: 415-429. PMID: 32542733, PMCID: PMC7848366, DOI: 10.1111/jvim.15806.Peer-Reviewed Original ResearchConceptsMast cell tumorsComplete responseControl dogsAdverse eventsIntratumoral treatmentTigilanol tiglateCell tumorsClinical studiesTumor volumeModified Response Evaluation CriteriaTT treatmentOverall complete responseResponse Evaluation CriteriaCanine mast cell tumorsPhase 1Quality of lifeConcomitant medicationsTumor resolutionLocal treatmentTreatment responseSolid tumorsDogsTumorsTreatmentEfficacy